News | Cardiovascular Clinical Studies | December 13, 2022

Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

Image courtesy of Intermountain Healthcare

Image courtesy of Intermountain Healthcare 


December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk factors, but researchers say it remains difficult to identify those at risk for an event before it happens. 

Intermountain researchers have been studying the puzzling trend of the high-frequency of heart attacks among people who don’t have commonly known modifiable risks for cardiovascular disease, including smoking, high-blood pressure, high cholesterol, and diabetes. 

For heart attacks that come from blocked arteries (ST-elevation heart attacks) it’s one in four patients. In heart attacks where oxygen is still getting to the heart but not enough (non-ST-elevation heart attacks, which are more common), it’s one in five patients. 

In the new study, Intermountain researchers examined non-ST-elevation heart attack patients and found that those without known modifiable risk factors fared better than those with them. 

These findings are important because they add to a body of research that, they hope, will lead to ways to identify who and why these patients are at risk of having heart attacks, and design better care methods to prevent them. 

Findings from the study were presented at the American Heart Association’s Scientific Sessions 2022 in Chicago on Sunday, Nov. 6, 2022. 

“This study showed us how many patients we see with these kinds of heart attacks, who were not obvious candidates for one, who were coming into our hospitals, and what their outcomes were,” said Jeffrey L. Anderson, MD, lead author of the study and cardiologist and heart researcher at the Intermountain Healthcare Heart and Vascular Program. “It’s not a small number, and we need to identify who is at risk.” 

“The best time to treat a heart attack is before you have one, and we need to figure out how we can help these kinds of patients before they do,” he added.  

In the retrospective study, Intermountain heart researchers identified 8,196 Intermountain patients who had a Non-ST-Elevation Myocardial Infarction (NSTEMI), the most common type of heart attack, where the artery isn’t completely blocked but the heart can’t get enough oxygen. 

Of those, 1,458 patients did not have any standard modifiable risk factors. Researchers then looked at patient outcomes, and their chance of having a major cardiac event 60 days later. 

They found that these patients were slightly less likely to have revascularization procedures than heart attack patients with known modifiable risk factors. They also had a lower chance of a subsequent major cardiac event or dying within that 60-day window. 

These findings helped Intermountain researchers quantify this patient population, according to Dr. Anderson, and to document their outcomes. A better outcome makes sense in that they appear to carry a lower burden of factors causing advanced disease. 

“But it does leave us with the question and the challenge of exactly how we identify these patients who are going to go have a heart attack who don’t have standard modifiable risk factors,” said Dr. Anderson. “The question is, can we identify them in advance and provide prevention measures?”  

“We also need to determine the non-standard risk factors that are present in these patients.” Intermountain researchers are currently exploring such options, including coronary calcium scans and blood tests for C-Reactive protein, which is a marker for inflammation, and lipoprotein (a), a lipid molecule not regularly tested for.  

For more information: https://intermountainhealthcare.org/ 


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now